News Focus
News Focus
icon url

jbog

01/25/19 8:32 AM

#223359 RE: DewDiligence #223358

There could be many adjustments taken in the 4th quarter but to see the U.S. portion of Mavyret fall 10% from the 3rd to 4th quarter is surprising.

More surprising is VPak's increase ex usa.

Again, there could be many explanations.
icon url

DewDiligence

01/25/19 10:30 AM

#223361 RE: DewDiligence #223358

ENTA +5%—ABBV’s 2019 HCV-sales guidance=$3.3B, -9% YoY.

GILD reports 4Q18 financials and gives 2019 guidance on 2/4/19.
icon url

DewDiligence

04/25/19 8:17 AM

#224762 RE: DewDiligence #223358

ABBV 1Q19 HCV sales=$815M—(-5% QoQ)—inline with 2019 guidance of $3.3B:

https://finance.yahoo.com/news/abbvie-reports-first-quarter-2019-114200769.html

US and ex-US HCV sales were $403M (flat QoQ) and $412M (-11% QoQ), respectively.